Scoring systems for the management of oncological hepato-pancreato-biliary patients

Abstract

Oncological scoring systems in surgery are used as evidence-based decision aids to best support management through assessing prognosis, effectiveness and recurrence. Currently, the use of scoring systems in the hepato-pancreato-biliary (HPB) field is limited as concerns over precision and applicability prevent their widespread clinical implementation. The aim of this review was to discuss clinically useful oncological scoring systems for surgical management of HPB patients. A narrative review was conducted to appraise oncological HPB scoring systems. Original research articles of established and novel scoring systems were searched using Google Scholar, PubMed, Cochrane, and Ovid Medline. Selected models were determined by authors. This review discusses nine scoring systems in cancers of the liver (CLIP, BCLC, ALBI Grade, RETREAT, Fong’s score), pancreas (Genç’s score, mGPS), and biliary tract (TMHSS, MEGNA). Eight models used exclusively objective measurements to compute their scores while one used a mixture of both subjective and objective inputs. Seven models evaluated their scoring performance in external populations, with reported discriminatory c-statistic ranging from 0.58 to 0.82. Selection of model variables was most frequently determined using a combination of univariate and multivariate analysis. Calibration, another determinant of model accuracy, was poorly reported amongst nine scoring systems. A diverse range of HPB surgical scoring systems may facilitate evidence-based decisions on patient management and treatment. Future scoring systems need to be developed using heterogenous patient cohorts with improved stratification, with future trends integrating machine learning and genetics to improve outcome prediction.

Salvage Hepatectomy for Recurrent Hepatocellular Carcinoma after Radiofrequency Ablation: A Retrospective Cohort Study with Propensity Score-Matched Analysis

“…There was no mortality during hospitalization in either group. The duration of postoperative hospital stay was similar between the two groups (SH 7 [5][6][7][8][9] days vs. PH 7 [5][6][7][8] days, p = 0.683).…”

“…Therapeutic options are chosen based on several factors, including tumor number and size, liver functional reserve, and general performance status [4]. The Barcelona Clinic Liver Cancer staging system defines curative treatment options for early HCC as surgical resection, liver transplantation, and thermal ablation [5,6]. Local ablation techniques, including a percutaneous ethanol injection, microwave ablation, and radiofrequency ablation (RFA), are widely used in clinical practice and accepted as first-line therapy for early HCC cases [7][8][9].…”

Immunotherapy improved cancer related pain management in patients with advanced Hepato-Pancreatic Biliary Cancers: A propensity score-matched (PSM) analysis

“…Hepatocellular carcinoma is also the second most common cause of cancer- related death. The American Cancer Society estimates that in 2021, there will be approximately 42,230 new cases of liver cancer in the United States ( 8 – 11 ). Cholangiocarcinoma (CCA) is a malignant tumor originating from bile duct epithelial cells that accounts for approximately 3% of tumors of the digestive system.…”